Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 5/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.34 |
| ▸ | CDK1 | P06493 | 4/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578323 | 0.85 | MAPK14 (0.37) | ABL1CDK2CCNA2CDK1CCNB1 | |
| SCHEMBL5578213 | 0.85 | CCNA2 (0.34) | ABL1CDK2CCNA2CDK1CCNB1 | |
| SCHEMBL5578472 | 0.84 | MAPT (0.34) | ABL1CDK2CCNA2CDK1CCNB1 | |
| SCHEMBL5578219 | 0.84 | ABL1 (0.35) | ABL1CDK2CCNA2CDK1CCNB1 | |
| SCHEMBL1645038 | 0.81 | CDK2 (0.40) | ABL1CDK2CCNA2CDK1CCNB1 | |
| SCHEMBL5578320 | 0.79 | ABL1 (0.37) | ABL1CDK2CCNA2CDK1CCNB1 | |
| SCHEMBL5578182 | 0.77 | PARP1 (0.34) | ABL1CDK2MAPTIRAK4TP53 | |
| SCHEMBL5578211 | 0.75 | ABL1 (0.34) | ABL1CDK2CCNA2CDK1CCNB1 | |
| SCHEMBL14511713 | 0.74 | CCNA2 (0.38) | ABL1CDK2CCNA2MAPTFGFR1 | |
| SCHEMBL14511688 | 0.74 | BRAF (0.32) | ABL1CDK2CCNA2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | ABL1 511/4885CDK2 5/4885CCNA2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.